Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

NCT01219192 is registered in ClinicalTrials.gov with Beijing Protgen Biotechnology Development Co., Ltd. as lead sponsor.

NCT NCT01219192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01219192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
Lead sponsor
Beijing Protgen Biotechnology Development Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2010
Completion date
December 31, 2011
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer